Mary F. Mulcahy, MD, and Crystal S. Denlinger, MD, on NCCN Guidelines Updates: Gastric and Esophageal Cancers

April 05, 2021 By The ASCO Post Staff

Crystal S. Denlinger, MD, of Fox Chase Cancer Center, and Mary F. Mulcahy, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discuss biomarkers for determining treatment; immune checkpoint inhibitors; when to employ such treatments as platinum/fluoropyrimidine and fam-trastuzumab deruxtecan-nxki; and other second- or later-line therapies such as paclitaxel, ramucirumab, irinotecan-based regimens, and trifluridine/tipiracil.

Related Content